CORCEPT THERAPEUTICS ($NASDAQ:CORT) announced their earnings results for the second quarter of fiscal year 2023 ending June 30 2023 on August 2 2023. The company reported total revenue of USD 117.7 million, a growth of 13.9% compared to the same period in the prior year. Net income was USD 27.5 million, an increase of 0.4% year over year.
The stock opened at $25.0 and closed at $25.0. This strong performance was attributed to robust sales of its drug Korlym, used in the treatment of Cushing’s syndrome. In addition to its strong financial performance, CORCEPT THERAPEUTICS also announced that it has plans to expand its product portfolio with two new treatments for rare diseases. The company is also expanding its research and development efforts into new therapeutic areas such as oncology and neurology.
CORCEPT THERAPEUTICS’ management team believes that these initiatives will further strengthen the company’s financial performance and position it as a leader in the pharmaceutical industry. The company’s CEO expressed optimism that CORCEPT THERAPEUTICS’ strong financial results will continue to drive long-term shareholder value. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Corcept Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Corcept Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Corcept Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Corcept Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale is the perfect platform to analyze CORCEPT THERAPEUTICS‘ financials. After looking into the company’s economic results, we have determined that it is a low risk investment in terms of financial and business aspects. It is always important to do thorough research before investing in any company. As part of our service, we also offer a risk rating that helps users make informed decisions. After looking into CORCEPT THERAPEUTICS’ financials, we have given it a low risk rating. GoodWhale is also able to detect specific risk warnings in the company’s income sheet. However, in order to access this information, users need to be registered with us. We always encourage our users to make sure that they are familiar with any risks associated with their investments. So if you would like to get a better understanding of CORCEPT THERAPEUTICS’ financials, you can register with us and take a look at the specific risk warnings that we have detected. More…
Risk Rating Analysis
Star Chart Analysis
The company’s competitors include RespireRx Pharmaceuticals Inc, Karyopharm Therapeutics Inc, and Shanghai Allist Pharmaceuticals Co Ltd.
– RespireRx Pharmaceuticals Inc ($OTCPK:RSPI)
The company’s market cap is 717.57k as of 2022 and its ROE is 10.74%. The company is a pharmaceutical company that focus on the development and commercialization of treatments for patients with respiratory diseases.
– Karyopharm Therapeutics Inc ($NASDAQ:KPTI)
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company that specializes in the development of drugs for the treatment of cancer and other diseases. The company has a market capitalization of 363.12 million as of 2022 and a return on equity of 46.62%. The company’s products are currently in clinical trials for the treatment of various types of cancer, including leukemia, lymphoma, and solid tumors.
– Shanghai Allist Pharmaceuticals Co Ltd ($SHSE:688578)
Shanghai Allist Pharmaceuticals Co Ltd is a pharmaceutical company with a market cap of 10.39B as of 2022. The company’s Return on Equity is 2.58%. Shanghai Allist Pharmaceuticals Co Ltd manufactures and sells pharmaceutical products in China. The company offers Western medicine, Chinese traditional medicine, health products, and medical devices. It also provides medical services.
CORCEPT THERAPEUTICS has achieved solid financial performance in the second quarter of 2023. Total revenue increased 13.9% year-over-year to USD 117.7 million, while net income rose 0.4% to USD 27.5 million. Investors should take note of the company’s ability to generate consistent top-line growth and maintain profitability despite challenging market conditions. Analysts may also want to consider the potential for further upside in the future, as the company has a pipeline of products and innovative treatments to bring to market.